title: Inhibiting the Jumonji family: a potential new clinical approach to targeting aberrant epigenetic mechanisms.
authors.affiliation: Hamon Center for Therapeutic Oncology Research, UT Southwestern Medical Center, Dallas, TX 75390, USA.|Department of Pharmacology, UT Southwestern Medical Center, Dallas, TX 75390, USA.|Harold C Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX 75390, USA.
authors.forename: Elisabeth D
authors.initials: ED
authors.lastname: Martinez
authors.affiliation: Hamon Center for Therapeutic Oncology Research, UT Southwestern Medical Center, Dallas, TX 75390, USA.|Department of Pathology, UT Southwestern Medical Center, Dallas, TX 75390, USA.|Harold C Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX 75390, USA.
authors.forename: Adi F
authors.initials: AF
authors.lastname: Gazdar
mesh_terms: D004791:Enzyme Inhibitors / Q000494:pharmacology*; D044127:Epigenesis, Genetic / Q000187:drug effects*; D056466:Histone Demethylases / Q000037:antagonists & inhibitors; D006801:Humans; D056484:Jumonji Domain-Containing Histone Demethylases / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D058990:Molecular Targeted Therapy / Q000379:methods; D000072417:Protein Domains
chemical_list: D004791:Enzyme Inhibitors; D056466:Histone Demethylases; D056484:Jumonji Domain-Containing Histone Demethylases; C495195:KDM1A protein, human
keywords: Jumonji family; Jumonji inhibitors; cancer; epigenetic reprogramming; epigenetic therapy; histone demethylation; lysine demethylation